# Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer

> **NCT05212857** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 160 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Leuprolide acetate
- **DRUG:** Goserelin acetate
- **DRUG:** Triptorelin acetate
- **DRUG:** Degarelix acetate
- **DRUG:** Abiraterone acetate
- **DRUG:** Apalutamide
- **DRUG:** Enzalutamide
- **PROCEDURE:** Local treatment for primary lesion
- **RADIATION:** Radiotherapy for primary lesion
- **RADIATION:** Radiotherapy for metastatic lesion

## Key facts

- **NCT ID:** NCT05212857
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04
- **Primary completion:** 2024-02
- **Final completion:** 2024-09
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2022-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05212857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05212857, "Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05212857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*